2026 Giant cell myocarditis indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 LMNA cardiomyopathy indication strategy covering epidemiology, LMNA biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Transthyretin cardiac amyloidosis wild-type indication strategy covering epidemiology, TTR biology, active trials, transactions, unmet need, competition and…

2026 Brugada syndrome type 1 indication strategy covering epidemiology, SCN5A biology, active trials, transactions, unmet need, competition and market…

2026 Progressive cardiac conduction disease indication strategy covering epidemiology, SCN5A biology, active trials, transactions, unmet need, competition and…

2026 Familial hyperaldosteronism type 3 indication strategy covering epidemiology, KCNJ5 biology, active trials, transactions, unmet need, competition and market…

2026 Familial hyperaldosteronism type 1 indication strategy covering epidemiology, CYP11B2 biology, active trials, transactions, unmet need, competition and…

2026 Apparent mineralocorticoid excess indication strategy covering epidemiology, HSD11B2 biology, active trials, transactions, unmet need, competition and…

2026 Pseudohypoaldosteronism type 1 indication strategy covering epidemiology, NR3C2 biology, active trials, transactions, unmet need, competition and market…

2026 Bartter syndrome type 4 indication strategy covering epidemiology, BSND biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Bartter syndrome type 3 indication strategy covering epidemiology, CLCNKB biology, active trials, transactions, unmet need, competition and market…

2026 Familial hypomagnesemia with hypercalciuria and nephrocalcinosis indication strategy covering epidemiology, CLDN16 biology, active trials, transactions,…